ZymoGenetics' Stock Falters as King Guards Thrombin Throne Excerpt: "Omrix's earnings, slated for Thursday, will provide the first clue to how the competition is shaping up." Should be interesting. Prediction: no sales. <a href="http://www.thestreet.com/_yahoo/newsanalysis/biotech/10406293.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA" target="_blank">http://www.thestreet.com/_yahoo/newsanalysis/biotech/10406293.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA</a>